Phase I study of vincristine, irinotecan, and 131I-MIBG for patients with relapsed or refractory neuroblastoma: A New Approach to Neuroblastoma Therapy (NANT) study

Authors :: Katherine K. Matthay
Randy Hawkins
Greg Yanik
Steven G. DuBois
Fariba Goodarzian
Yael P. Mosse
Clinton F. Stewart
S. Groshen
Louis Chesler
Judith G. Villablanca
John M. Maris
Source :: Journal of Clinical Oncology. 29:9513-9513
Publication Year :: 2011
Publisher :: American Society of Clinical Oncology (ASCO), 2011.
Abstract: 9513 Background: 131I-metaiodobenzylguanidine (MIBG) is a targeted radiopharmaceutical with activity in neuroblastoma. Irinotecan is a radiosensitizer with activity in neuroblastoma. This phase I s...

Subjects :: Oncology
Cancer Research
Vincristine
Radiosensitizer
medicine.medical_specialty
business.industry
Pharmacology
medicine.disease
digestive system diseases
Phase i study
Irinotecan
Refractory
131i mibg
Neuroblastoma
Internal medicine
Medicine
business
neoplasms
medicine.drug

Tools